NCT04614051 is a Phase 1 clinical trial of Cellgram-DC in Ovarian Cancer, sponsored by Pharmicell Co., Ltd..

Who is sponsoring NCT04614051?

NCT04614051 is sponsored by Pharmicell Co., Ltd..

What drugs are being tested in NCT04614051?

Interventions in NCT04614051: Cellgram-DC.

What condition does NCT04614051 study?

NCT04614051 studies Ovarian Cancer.

Is NCT04614051 still recruiting?

NCT04614051 is currently terminated. Last updated 3 January 2023.

Last reviewed 2023-01-03 · How we verify

NCT04614051

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC)

Terminated Phase 1 Last updated 3 January 2023

What this trial tests

Phase 1 trial testing Cellgram-DC in Ovarian Cancer in 2 participants. Terminated before completion.

Timeline

30 March 2021

Primary endpoint
10 May 2022

10 May 2022

Quick facts

Lead sponsor	Pharmicell Co., Ltd.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	30 March 2021
Primary completion	10 May 2022
Estimated completion	10 May 2022
Sites	1 location across South Korea

Drugs / interventions tested

Cellgram-DC — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Pharmicell Co., Ltd. — full company profile →

Who can join

Adults 19 to 79, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1 study to evaluate the safety of cancer immunotherapy with autologous dendritic cells in patients with advanced or recurrent epithelial ovarian cancer

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, et al · · 2022 · cited 101× · PMID 35800158 · DOI 10.1080/2162402x.2022.2096363
Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer.
Caro AA, Deschoemaeker S, Allonsius L, Coosemans A, et al · · 2022 · cited 22× · PMID 36011029 · DOI 10.3390/cancers14164037
Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano RS, Vanmeerbeek I, Sprooten J, et al · · 2024 · cited 18× · PMID 39398476 · DOI 10.1080/2162402x.2024.2412876
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.
Chiang CL, Rovelli R, Sarivalasis A, Kandalaft LE. · · 2021 · cited 8× · PMID 34572778 · DOI 10.3390/cancers13184553
Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review.
Nezamdoust FV, Nezhad-Mokhtari P, Mirzaahmadi B, Mazloumi Z, et al · · 2026 · PMID 42010708 · DOI 10.1186/s13287-026-05011-7

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Pharmicell Co., Ltd. trials

Trials by the same sponsor.

NCT07431008 — Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction · recruiting
NCT07400458 — Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration · NA · recruiting
NCT05042206 — Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease · Phase 1 · completed
NCT05093881 — Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study · NA · recruiting
NCT04615845 — Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04614051 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pharmicell Co., Ltd.
Last refreshed: 3 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04614051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing